JB Pharma acquires rosuvastatin brand from Glenmark for Rs 314 crore

The acquisition will be funded through long term debt and internal accruals. Razel ranks among the top 10 brands in India in the rosuvastatin molecule category, with the combined sales of Rs 66.1 crore as of year end October 2022 as per IQVIA data.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news